诺和诺德盘前跌超8%，公司表示，抗炎药物Ziltivekimab在MACE风险降低方面与安慰剂相比未显示出显著差异。
诺和诺德盘前跌超8%，公司表示，抗炎药物Ziltivekimab在MACE风险降低方面与安慰剂相比未...
其他语言标题
- EnglishNovo Nordisk fell over 8% in pre-market trading, as the company stated that the anti-inflammatory drug Ziltivekimab did not show a reduction in MACE risk compared to a placebo...